[Treatment of renal vein thromboses in the newborn].
Surgical thrombectomy is not a rational approach to neonatal renal vein thrombosis since the occlusion mainly involves intrarenal branches rather than the main renal vein, which is even patent in some instances. Conservative management combines supportive therapy for renal failure and systemic hypertension, if needed, and either heparin or thrombolytic agents. Streptokinase has proven difficult to handle in neonates and should not be used. Urokinase has been used in 18 patients but results are difficult to interpret because these cases occurred over an 18-year period. Plasminogen tissue activator, the latest thrombolytic agent developed, has been used in few pediatric patients. An international task force is currently studying whether or not a randomized study is warranted to provide data for standardizing thrombolytic therapy in pediatric renal vein thrombosis.
Beaufils
F
F
Service de Réanimation Pédiatrique, Hôpital Robert Debré, Paris.
Schlegel
N
N
Brun
P
P
Loirat
C
C
D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009359:Neonatology / Q000379:methods* / Q000592:standards; D009392:Nephrectomy / Q000592:standards; D012082:Renal Veins; D017131:Thrombectomy / Q000592:standards; D013927:Thrombosis / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D006493:Heparin